Gweon Tae-Geun, Na Soo-Young
Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Division of Gastroenterology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
Clin Endosc. 2021 Mar;54(2):152-156. doi: 10.5946/ce.2021.053. Epub 2021 Mar 24.
Fecal microbiota transplantation (FMT) is considered as an effective treatment for Clostridioides difficile infection. However, the precise mechanism of FMT is yet to be determined. Human stool consists of the gut microbiota, bacterial debris, and metabolic products. Of these, the intestinal microbiota is the most important factor that exerts therapeutic efficacy in FMT. Fresh donor stool, blended with normal saline, has been employed for traditional FMT. Nevertheless, stool processing is a major impediment in FMT. Frozen stool and capsule formulations have similar efficacy to that of fresh stool. In addition, several novel stool products have been identified. A stool bank that provides stool products with pre-screened donor stool has been established to help physicians and thereby facilitate FMT. Recent next-generation sequencing techniques have been key in facilitating the detailed analysis of the microbiota and gut environment of individual donors and recipients.
粪便微生物群移植(FMT)被认为是治疗艰难梭菌感染的有效方法。然而,FMT的确切机制尚待确定。人类粪便由肠道微生物群、细菌碎片和代谢产物组成。其中,肠道微生物群是在FMT中发挥治疗效果的最重要因素。与生理盐水混合的新鲜供体粪便已被用于传统的FMT。然而,粪便处理是FMT的一个主要障碍。冷冻粪便和胶囊制剂与新鲜粪便具有相似的功效。此外,还发现了几种新型粪便产品。已经建立了一个粪便库,提供经过预先筛选的供体粪便制成的粪便产品,以帮助医生,从而促进FMT。最近的下一代测序技术对于促进对个体供体和受体的微生物群及肠道环境进行详细分析起到了关键作用。